ProtoKinetix (OTCBB: PKTX), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries announced, as a follow up to recent news on the research done by ProtoKinetix’ lead scientific investigator, Dr. Samer Hussein, the Company announces some of his findings as related to stem cell recovery.
Using a standard cryogenic protocol for stem cell storage, the addition of 2mg/ml of AAGP™ resulted in an extraordinary recovery of 87-percent. Traditional recovery rates after cryopreservation with DMSO are typically between 30 and 40-percent.
In addition to the value of AAGP™ in cryopreservation (frozen to -196˚C), a set of trials designed to determine whether AAGP™ treated stem cells could survive after refrigeration (4˚C) were conducted. After 3-days of refrigeration, untreated cells have a very high mortality rate. These trials found that AAGP™ can significantly reduce cell death rate. AAGP™ demonstrated an impressive and repetitive 8 to 12-times increase in cell viability and survivability.
“Preservation of stem cells is getting to be more and more popular given the disease fighting regenerative ability of the stem cells. These results with AAGP™ opens up an ever expanding market for ProtoKinetix which we fully intend to take advantage of, said Ross L. Senior, President and CEO of ProtoKinetix, Inc.
Source: ProtoKinetix